Butyrate Cancer Research Results

BA, Butyrate: Click to Expand ⟱
Features:

Butyrate — a four-carbon short-chain fatty acid produced mainly by gut microbial fermentation of dietary fiber, functioning as both a colonocyte energy substrate and a pleiotropic signaling metabolite. It is formally classified as an endogenous microbial metabolite and short-chain fatty acid; common research and delivery forms include sodium butyrate and the oral prodrug tributyrin. Standard abbreviations include butyrate, NaBu, SCFA, and TB for tributyrin. Its source is primarily the colonic microbiome–fiber axis, with highest physiological relevance in the colon lumen and colonic epithelium rather than in systemic circulation. In cancer biology, its effects are highly context-dependent: it is most mechanistically credible in colorectal and inflammation-linked gastrointestinal settings, while newer tumor-microbiome data indicate that intratumoral butyrate can also support progression in some non-colorectal contexts.

Primary mechanisms (ranked):

  1. HDAC inhibition with histone hyperacetylation, driving differentiation, cell-cycle arrest, apoptosis, and altered immune-regulatory transcription.
  2. Warburg-dependent metabolic partitioning (“butyrate paradox”), in which normal colonocytes oxidize butyrate as fuel whereas glycolytic colorectal cancer cells accumulate it and become more HDAC-inhibition-sensitive.
  3. GPCR signaling through HCAR2 GPR109A, FFAR2 GPR43, and FFAR3 GPR41, shaping epithelial barrier function, inflammasome and IL-18 programs, and immune tone.
  4. Secondary metabolic reprogramming, including suppression of glycolytic dependence in some colorectal cancer models.
  5. Context-dependent modulation of inflammatory signaling, autophagy, and oxidative-stress handling.

Bioavailability / PK relevance: Butyrate is rapidly absorbed and extensively metabolized, so systemic exposure is limited and transient. Physiologic and therapeutic relevance is therefore mainly local to the colon; oral strategies that matter most are colonic-release sodium butyrate, microbiome/fiber approaches, or tributyrin-type prodrugs that improve delivery.

In-vitro vs systemic exposure relevance: Many cancer-cell studies use roughly 0.5–5 mM, with some using higher concentrations. Those ranges are plausible in the colonic lumen and at the epithelial interface, where butyrate commonly reaches about 10–20 mM, but they are generally not representative of sustained plasma exposure after ordinary oral dosing.

Clinical evidence status: Preclinical for direct anticancer efficacy; small early-phase human oncology studies exist for tributyrin and other butyrate-delivery approaches, but no established antitumor standard-of-care role is supported. Human evidence is stronger for GI-supportive or radiotherapy-supportive use than for tumor control.

Butyrate mechanistic matrix

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 HDAC inhibition and histone acetylation programs ↑ histone acetylation; ↓ proliferation; ↑ differentiation; ↑ apoptosis ↑ histone acetylation with predominantly homeostatic and anti-inflammatory effects R→G Epigenetic reprogramming Most central direct mechanism, especially when intracellular butyrate accumulates beyond oxidative disposal capacity.
2 Warburg-dependent fuel versus accumulation axis ↓ butyrate oxidation in glycolytic CRC models → ↑ intracellular butyrate → stronger HDACi phenotype ↑ butyrate oxidation as mitochondrial fuel in differentiated colonocytes R Context-selective anticancer leverage This “butyrate paradox” is the key framework explaining why butyrate can support normal colon epithelium yet inhibit many colorectal cancer cells.
3 HCAR2 GPR109A and FFAR2 FFAR3 receptor signaling ↓ pro-tumor inflammation; ↑ apoptosis in receptor-competent contexts ↑ barrier support; ↑ epithelial repair signaling; ↑ immune homeostasis P→R Receptor-mediated epithelial and immune regulation Mechanistically meaningful but usually secondary to HDAC biology in direct cancer-cell systems; more important in mucosal and microenvironmental settings.
4 IL-18 inflammasome-linked mucosal defense axis ↔ or ↓ inflammation-associated carcinogenic signaling ↑ IL-18 and mucosal defense programs R→G Barrier and immune surveillance support Most relevant to inflammation-linked colorectal carcinogenesis rather than broad pan-cancer cytotoxicity.
5 Glycolysis and glucose-use reprogramming ↓ glycolytic dependence; ↓ Warburg phenotype (model-dependent) ↔ or ↑ oxidative utilization of butyrate R→G Metabolic normalization in subset models Best supported in colorectal systems; not a universal butyrate effect across all tumors.
6 NF-κB and inflammatory signaling ↓ inflammatory and immunosuppressive signaling (context-dependent) ↓ inflammatory tone P→R Microenvironmental anti-inflammatory effect Often relevant in IBD-CRC and GI-supportive settings; should not be overinterpreted as a stand-alone tumoricidal mechanism.
7 Mitochondrial ROS increase (secondary) ↔ or ↑ ROS and apoptosis signaling (high concentration only; model-dependent) ↔ or ↓ oxidative stress indirectly via barrier and inflammatory control R Stress-amplified apoptosis in subset models ROS is usually downstream and secondary, not a core primary mechanism of butyrate action.
8 NRF2 adaptive antioxidant signaling (secondary) ↔ (context-dependent) ↔ or ↑ cytoprotective adaptation G Stress adaptation NRF2 is not a canonical primary axis for butyrate and should remain secondary unless a model directly demonstrates it.
9 Autophagy and apoptosis coupling ↑ autophagy or apoptosis depending on model and dose ↔ R→G Cell-fate modulation Seen in some bladder and colorectal systems, but not central enough to outrank HDAC and metabolic axes.
10 Metastatic microenvironment context dependence ↔ or ↑ progression in some intratumoral-microbiome settings ↔ G Context-dependent risk constraint Recent evidence shows intratumor microbiome-derived butyrate can promote metastasis in some lung cancer settings, so butyrate should not be treated as uniformly antitumor.
11 Clinical Translation Constraint Rapid absorption and metabolism limit sustained systemic exposure; strongest rationale is colon-local delivery, microbiome/fiber modulation, or prodrug approaches. Human oncology evidence remains early-phase or supportive-care oriented rather than definitive for tumor control. — PK / Delivery / Evidence Important final constraint row because many in-vitro concentrations are colon-local rather than systemically achievable.

TSF legend: P: 0–30 min (primary/rapid effects) | R: 30 min–3 hr (acute signaling + stress responses) | G: >3 hr (gene-regulatory adaptation; phenotype outcomes)
Scientific Papers found: Click to Expand⟱
1032- BA,    Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer
- in-vivo, GC, AGS
GutMicro↑, PD-L1↓, IL10↓, TumCG↓,
1080- BA,    Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition
- in-vitro, CRC, HT-29
HDAC↓, TNF-α↓, COX2↓,
1224- BA,    Intratumor microbiome-derived butyrate promotes lung cancer metastasis
- in-vivo, Lung, NA
TumCG↑, H19↑, HDAC2↓,
2047- BA,    Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells
- in-vitro, CRC, T24/HTB-9 - in-vitro, Nor, SV-HUC-1 - in-vitro, Bladder, 5637 - in-vivo, NA, NA
HDAC↓, AntiTum↑, TumCMig↓, AMPK↑, mTOR↑, TumAuto↑, ROS↑, miR-139-5p↑, BMI1↓, TumCI?, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, Bcl-xL↓, MMP↓, PINK1↑, PARK2↑, TumMeta↓, TumCG↓, LC3II↑, p62↓, eff↓,
2050- BA,    The Role of Sodium Phenylbutyrate in Modifying the Methylome of Breast Cancer Cells
- in-vitro, BC, MCF-7
eff↑, HDAC↓, TumCG↓,
5731- BA,    The Warburg Effect Dictates the Mechanism of Butyrate Mediated Histone Acetylation and Cell Proliferation
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
HDAC↓, Warburg↓, TumCP⇅, HATs↑, BioAv↓,
3236- EGCG,  BA,    Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate
- in-vitro, Colon, RKO - in-vitro, Colon, HCT116 - in-vitro, Colon, HT29
Apoptosis↑, TumCCA?, HDAC1↓, DNMT1↓, survivin↓, HDAC↓, P21↑, NF-kB↑, γH2AX↑, ac‑H3↑, DNAdam↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

PARK2↑, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   PINK1↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   Warburg↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   cl‑Casp3↑, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

H19↑, 1,   ac‑H3↑, 1,   HATs↑, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   DNMT1↓, 1,   cl‑PARP↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA?, 1,  

Proliferation, Differentiation & Cell State ⓘ

BMI1↓, 1,   HDAC↓, 5,   HDAC1↓, 1,   HDAC2↓, 1,   mTOR↑, 1,   TumCG↓, 3,   TumCG↑, 1,  

Migration ⓘ

E-cadherin↑, 1,   miR-139-5p↑, 1,   N-cadherin↓, 1,   Snail↓, 1,   TumCI?, 1,   TumCMig↓, 1,   TumCP⇅, 1,   TumMeta↓, 1,   Vim↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL10↓, 1,   NF-kB↑, 1,   PD-L1↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   eff↓, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 51

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:50  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page